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Summary
Transglutaminase 2 (TG2) is expressed ubiquitously, has multiple physiologi-
cal functions and has also been associated with inflammatory diseases, neu-
rodegenerative disorders, autoimmunity and cancer. In particular, TG2 is
expressed in small intestine mucosa where it is up-regulated in active coeliac
disease (CD). The aim of this work was to investigate the induction of TG2
expression by proinflammatory cytokines [interleukin (IL)-1, IL-6, tumour
necrosis factor (TNF)-a, interferon (IFN)-g and IL-15] and the signalling
pathways involved, in human epithelial and monocytic cells and in intestinal
tissue from controls and untreated CD patients. Here we report that IFN-g
was the most potent inducer of TG2 expression in the small intestinal mucosa
and in four [Caco-2, HT-29, Calu-6 and human acute monocytic leukaemia
cell line (THP-1)] of five cell lines tested. The combination of TNF-a and
IFN-g produced a strong synergistic effect. The use of selective inhibitors of
signalling pathways revealed that induction of TG2 by IFN-g was mediated by
phosphoinositide 3-kinase (PI3K), while c-Jun N-terminal kinase (JNK) and
p38 mitogen-activated protein kinase (MAPK) were required for TNF-a
activation. Quantitative polymerase chain reaction (PCR), flow cytometry
and Western blot analysis showed that TG2 expression was blocked com-
pletely when stimulation by either TNF-a or IFN-g was performed in the
presence of nuclear factor (NF)-kB inhibitors (sulphasalazine and BAY-
117082). TG2 was up-regulated substantially by TNF-a and IFN-g in intesti-
nal mucosa in untreated CD compared with controls. This study shows that
IFN-g, a dominant cytokine in intestinal mucosa in active CD, is the most
potent inducer of TG2, and synergism with TNF-a may contribute to exacer-
bate the pathogenic mechanism of CD. Selective inhibition of signalling
pathways may be of therapeutic benefit.
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Introduction
Transglutaminases are enzymes that catalyse, in a calcium-
dependent manner, the cross-linking of proteins by
e-(g-glutamyl) lysine isopeptide bonds, creating highly
cross-linked protein complexes, or alternatively the deami-
dation of specific glutamine residues in the absence of suit-
able amine acceptors. Although their primary structure is
not conserved, different transglutaminases have the same
amino acid sequence at their active sites [1]. Tissue trans-
glutaminase 2 (TG2) (EC 2·3.2·13) is the best-studied
member of this family because of its multiple biological
activities including, as a G protein, cell surface adhesion
adaptor, disulphide isomerase and serine/threonine kinase
[2,3]. The sequence of the complete TG2 gene obtained from
the human intestinal epithelial cell line Caco-2 published by
us in the National Institutes of Health (NIH) database [4],
codifies for a protein of 687 amino acids long. TG2 acts as a
monomer and has two closely located binding regions, one
for Ca2+ and one for GTP, as TG2 also has GTPase activity.
TG2 is expressed ubiquitously and has multiple physiological
functions in processes such as blood clotting, wound healing,
cell adhesion, cell signalling and apoptosis, among others
[1–3]. TG2 has also been associated with pathological con-
ditions, mainly inflammatory diseases such as encephalomy-
elitis and inflammatory myopathies, and neurodegenerative
Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/j.1365-2249.2011.04545.x
95© 2011 The Authors
Clinical and Experimental Immunology © 2011 British Society for Immunology, Clinical and Experimental Immunology, 168: 95–104
disorders such as Alzheimer’s, Parkinson’s and Huntington’s
diseases, as well as various types of cancer [5–7].
TG2 is involved at different molecular levels in the patho-
logical processes of these disorders, associated mainly with
protein cross-linking or deamidation, as well as regulation of
apoptosis. In particular, TG2 plays a critical role in the
pathogenesis of coeliac disease (CD), because it is able to
deamidate glutamine residues present in toxic proteins from
wheat and related cereals. The deamidation of glutamine at
selective positions leads to higher-affinity binding of deami-
dated peptides to human leucocyte antigen (HLA) proteins
encoded by the CD predisposing alleles DQ2 (A1*0501,
B1*0201) and DQ8 (A1*0301, B1*0302), and also to a higher
gliadin-specific T cell stimulation [8–10].
The TG2 gene is regulated by the canonical nuclear factor
(NF)-kB pathway in several cell lines, and it has been
reported that in cancer and microglial cells TG2 can activate
NF-kB by blocking the inhibitor function of IkBa via
polymer formation [11]. Consequently, there is a complex
cross-regulation between TG2 activity and the NF-kB
pathway, a mechanistic link that can be observed in inflam-
mation and cancer. TG2 expression in human liver cells [12],
intestinal epithelial cells [13] and rat small intestine cells [14]
can be induced by proinflammatory cytokines such as inter-
leukin (IL)-1, tumour necrosis factor (TNF)-a and inter-
feron (IFN)-g, thus amplifying the inflammatory cascade.
Therefore, the development of specific TG2 inhibitors with
reduced in-vivo toxicity could represent a novel therapeutic
approach with the aim of modulating TG2 activity and
reduce, or even abolish, the disease processes where the
enzyme activity is dysregulated [15]. To this end, more
detailed information about the biology and molecular regu-
lation of the TG2 gene in inflammatory settings is needed.
In this study, we evaluated the regulation of the TG2
expression by proinflammatory cytokines in different cell
lines and particularly in the intestinal mucosa. We found that
IFN-g is the most potent inducer of TG2 expression, and acts
synergistically with TNF-a. Using different inhibitors we
also identified the signalling pathways used by each cytokine
for TG2 up-regulation.
Materials and methods
Cell culture and treatments
Five human cell lines from different cell lineages were used:
intestinal epithelial cells: Caco-2 (Caucasian, colon, adeno-
carcinoma) and HT29 (Caucasian, colon, adenocarcinoma,
grade II); lung epithelial cells: A549 (Caucasian, lung, carci-
noma) and CALU-6 (Caucasian, lung, adenocarcinoma);
and a monocyte-like cell line: human acute monocytic leu-
kaemia cell line (THP-1). Cells were incubated with cyto-
kines alone or with the addition of inhibitors for different
time-periods (from 45 min to 48 h). Cytokine treatments
were as follows: TNF-a 10 ng/ml (RTNFA1; Endogen,
Woburn, MA, USA), IFN-g 200 UI/ml (554617; Becton
Dickinson, Franklin Lakes, NJ, USA), IL-1 10 ng/ml (551838;
Becton Dickinson), IL-6 10 ng/ml (354075; Becton Dic-
kinson) and IL-15 20 ng/ml (554630; Becton Dickinson).
In some cases inhibitors of signalling pathways were
used: SP600125 20 mM [c-Jun N-terminal kinase (JNK)],
SB203580 10 mM [p38-mitogen-activated protein kinase
(MAPK)], wortmannin 10 mM [phosphoinositide 3-kinase
(PI3K)] (from Calbiochem, Germany), Ly294002 2 mM
(PI3K), sulphasalazine 10 mM (NF-kB) and BAY11-7082
1 mM (NF-kB) (from Sigma, St Louis, MO, USA). Finally,
cells were harvested for real-time polymerase chain reaction
(RT–PCR), Western blot or flow cytometry analysis.
Duodenal samples
Duodenal mucosal biopsy specimens were taken from five
patients with CD and from seven normal controls. Adult
patients were evaluated employing the routine procedure for
CD diagnosis at the San Martin Hospital, La Plata. CD
patients were diagnosed on the basis of histological exami-
nation, positive serology and clinical response to a gluten-
free diet. Control samples were taken from non-coeliac
patients referred for gastroendoscopy because of other
conditions (oesophagitis, abdominal pain, diarrhoea, iron
deficiency anaemia).
The study was approved by the committee for medical
research ethics, and all patients gave written consent before
participating.
For transport, duodenal tissue specimens were inserted
rapidly into sterile tubes containing 3 ml of Ham’s F12
medium (Gibco, Carlsbad, CA, USA) supplemented with
penicillin and streptomycin (Gibco). Then, biopsy samples
were washed gently three times with phosphate-buffered
saline (PBS) and incubated in Ham’s F12 medium (Gibco)
with cytokines alone (TNF-a 10 ng/ml, IFN-g 200 UI/ml) or
with the addition of inhibitors (Ly294002 2 mM, sulphasala-
zine 10 mM) for 24 h at 37°C in 5% CO2. Finally, total RNA
was isolated using Trizol reagent (Invitrogen, Carlsbad, CA,
USA).
Quantitative RT–PCR (qRT–PCR)
Total RNA was isolated using Trizol reagent. Reverse tran-
scription was performed at 25°C for 10 min, 37°C for 1 h and
72°C for 5 min from 100 ng of total RNA using M-MLV
reverse transcriptase (Promega, Madison, Wisconsin, USA)
and random primers (1 mM; Invitrogen). qPCR was per-
formed in iCycler real time PCR (Bio-Rad, Munich,
Germany) using SybrGreen mix (Invitrogen). The TG2
primers (forward: 5′-TCAACTGCAACGATGACCAGG-
3′; reverse: 5′-TGTTCTGGTCATGGGCCGAG-3′) were
designed with the Chromas Primer Designer program. The
running protocol was as follows: cycle 1 (¥1) 95°C 10 min;
cycle 2 (¥50) 95°C 15 s, 57°C 15 s, 72°C 30 s; cycle 3 (¥81)
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55–95°C 30 s. The comparative Ct method was used to quan-
tify TG2 transcript and normalization was performed with
the b-actin housekeeping gene. Values are expressed as
mean 6 standard deviation (s.d.) of the mean. Representa-
tive experiments were performed three times and analysed
statistically using the Mann–Whitney U-test.
Western blot analysis
For protein extraction treated cells were washed twice with
ice-cold PBS, scraped off with 0·4 ml of PBS and subjected to
a short centrifugation (10 s, room temperature, 14·000 g).
The supernatant was discarded and the pellet was resus-
pended in freeze/thaw lysis buffer. The suspension was
frozen briefly in N2 and was allowed to thaw slowly on ice.
The freeze/thaw cycle was repeated three more times. After
vortexing for 10 s, the lysates were incubated with DNAse
(Invitrogen) for 20 min at 37°C, and finally stored at -80°C.
Protein concentration was determined by the bicinchoninic
acid assay (BCA; Pierce, Rockford, IL, USA).
Laemmli gel sample buffer was added to the lysate con-
taining 10 mg of protein and boiled for 7 min, after which
proteins were separated by sodium dodeyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) electro-
phoresis on a 12·5% gel. Proteins from the gel were
electrotransferred to a polyvinylidene difluoride (PDVF)
membrane (Bio-Rad Laboratories, Hercules, CA, USA).
After 2 h incubation in blocking solution [5% dry milk
in Tris-buffered saline–Tween (TBST) 20 buffer] the
membrane was incubated with the mouse anti-TG2 mono-
clonal antibody 4E1G9 produced and characterized in our
laboratory [16], and with a rabbit anti b-actin antibody
(Abcam, Cambridge, UK), according to the manufacturer’s
recommendations. The membrane was then washed
three times with TBST and incubated with horseradish
peroxidase-conjugated secondary antibodies (Amersham
Biosciences, Piscataway, NJ, USA) for 1 h at room
temperature. The membrane was rinsed three times for
20 min with TBST, followed by four quick rinses with dis-
tilled water, and developed with 4-chloro-naphthol/H2O2
and methanol.
Cloning and expression of TG2
TG2 was amplified from Caco-2 cells by PCR and cloned into
pET28 vector (Novagen, Madison, WI, USA). The protein
was expressed in Escherichia coli Rosetta 2 (DE3) cells using
lysogeny broth (LB) culture medium. Protein expression was
induced with 100 mM isopropyl b-d-thiogalactopyranoside
(Invitrogen) and the cells were incubated further for 24 h at
28°C. The cells were then lysed in a lysis buffer [50 mM
sodium-phosphate pH 7·5, 400 mM sodium chloride, 5 mM
imidazole, 0·5% (v/v) Triton-X100]. The crude lysate was
centrifuged at 21 000 g for 20 min, and the superna-
tant was applied to a Ni-NTA column (Qiagen, Hilden,
Germany). After several washings with wash buffer (50 mM
sodium-phosphate pH 7·5, 500 mM sodium chloride,
60 mM imidazole), the protein was eluted with elution
buffer [50 mM Hepes pH 7·0, 100 mM sodium chloride,
300 mM imidazole, 10% (v/v] glycerol), after which the
eluted protein fractions were pooled and concentrated.
Recombinant TG2 protein (rTG2) was used as a reference in
Western blot analysis.
Reporter system with TG2 promoter
A fragment of 1·5 Kb long of the TG2 promoter region from
Caco-2 cells was cloned in a firefly luciferase reporter vector
pGL3 (Promega). Caco-2 cells were plated in a 24-well plate
and transfected transiently with TG2 promoter construction
together with a Renilla luciferase vector. Transient transfec-
tion was carried out using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions. Briefly, cells
were seeded at a density of 4·105 per well in a six-well plate.
When cells reached 40–50% confluence they were washed
with 2 ml Opti-MEM (Invitrogen) and incubated with
a DNA-Lipofectamine (Invitrogen) mixture for 6 h in a
humidified 5% CO2 environment. After 6 h of incubation
the transfection medium was replaced with fresh culture
medium, and cells were incubated for 24 h. Subsequently,
cells were incubated with cytokines alone (TNF-a 10 ng/ml,
IFN-g 200 UI/ml) or with the addition of inhibitors of
signalling pathways (SP600125 20 mM, Ly294002 2 mM, sul-
phasalazine 10 mM) for another 24 h. Luciferase activity
was measured in cellular lysates using the Dual-Luciferase
Reporter Assay System Kit (Promega), according to the
manufacturer’s protocol. For each sample firefly luciferase
data were normalized to the Renilla luciferase internal
control. Relative luciferase units (RLU) are referred to the
non-stimulated control.
Flow cytometry
To evaluate the expression of surface TG2, THP-1 cells were
treated for 20 h with TNF-a 10 ng/ml and IFN-g 200 UI/ml,
and inhibitors of signalling pathways. Cells were incubated
with the anti-TG2 monoclonal antibodies (4E1G9, 2G3H8,
5G7G6 or 1H7H9) produced in our laboratory [16]. Then
cells were incubated with fluorescein isothiocyanate-
conjugated goat anti-mouse immunoglobulin (Ig)G (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Flow cytometry
analysis was performed in a fluorescence activated cell sorter
(FACS)Calibur flow cytometer (BD Biosciences), and data
were analysed using FlowJo software (Tree Stars, Ashland,
OR, USA).
Results
Proinflammatory cytokines regulate TG2 expression
To investigate whether the proinflammatory cytokines
TNF-a, IFN-g, IL-15, IL-6 and IL-1 modulate TG2
IFNg and TNFa enhance TG2 expression
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expression, we measured TG2 mRNA levels by quantitative
(q)RT–PCR in five human cell lines from different cell lin-
eages (Caco-2 and HT29, intestinal epithelia; A549 and
CALU-6, lung epithelia; THP-1, monocyte-like) stimulated
for 24 h with the cytokines mentioned. In all cell lines tested,
except for A549, IFN-g was the most potent inducer of TG2
expression (Fig. 1). The highest induction of TG2 by IFN-g
was observed in THP-1 cells (fold increase = 20·2). In the
two intestinal epithelial cell lines, Caco-2 and HT29, the
up-regulation of TG2 transcript by IFN-g was about 18-fold
while TG2 levels were increased by 6·9- and 7·3-fold in A549
and CALU-6, respectively. TG2 was also induced by TNF-a
stimulation, this cytokine being the second most potent
inducer in three (Caco-2, Calu-6 and THP-1) of the five cell
lines tested. Concentration of cytokines used for cell treat-
ment was selected according with the respective dose–
response curve (Supporting Information, Fig. S1), which was
also similar to those used in another study [14], among other
reports. Cell viability was checked for each treatment condi-
tion (Supporting Information, Fig. S2). Stimulation with
IL-1 and IL-15 produced a much lower induction of TG2
expression, causing a 7·9- and 7·8-fold increase, respectively.
IL-1 produced the highest TG2 induction in A549 cells,
whereas IL-6 incubation produced small increases ($five-
fold) in TG2 mRNA levels in all cell lines tested.
Synergistic effect of TNF-a and IFN-g
on TG2 expression
Because both IFN-g and TNF-a are cytokines involved in the
pathogenic mechanisms of different inflammatory diseases,
and were shown here to induce the transcription of TG2
mRNA, we evaluated further the effect of these two cytokines
on TG2 expression. Cells were incubated for 24 h with
TNF-a, IFN-g or a combination of both cytokines. In all cells
tested, the incubation with TNF-a + IFN-g produced a
much higher induction of TG2 mRNA than the individual
cytokines alone (Fig. 2). Treatment with TNF-a and IFN-g
produced a synergistic effect in four (Caco-2, A549, CALU-6
and THP-1) of the five cell lines tested.
Kinetics of TG2 induction by TNF-a + IFN-g
To investigate the time–course of the synergistic TG2 induc-
tion, THP-1 and Caco-2 cells were stimulated with TNF-
a + IFN-g for different time-periods (from 45 min to 48 h)
and TG2 mRNA was determined by qRT–PCR (Supporting
Information, Fig. S3). The kinetics of TG2 induction were
equivalent for both cell lines, with the maximal induction
observed at 16 h post-stimulation. In agreement with pre-
vious results, TG2 induction was higher in THP-1 cells
(41-fold) compared with Caco-2 cells (28-fold) at 16 h post-
stimulation. In spite of the biological differences between
these two cell lines, these results suggest that the intracellular
mechanisms leading to induction of TG2 expression are
equivalent in both cell lines.
Effect of selective inhibition of signalling pathways
on TG2 expression
It has been described that TNF-a activates multiple signal-
ling pathways such as those of NF-kB, p38 mitogen-activated
Fig. 1. Proinflammatory cytokines regulate
transglutaminase 2 (TG2) expression in human
cell lines. Expression of TG2 was determined by
quantitative real time polymerase chain reaction
(RT–PCR) in five different human cell lines:
intestinal epithelial cell lines Caco-2 and HT29,
lung epithelial cell lines A549 and Calu-6 and
the monocytic cell line human acute monocytic
leukaemia cell line (THP-1) (lower panel of the
chart) stimulated for 24 h with proinflammatory
cytokines: tumour necrosis factor (TNF)-a
(10 ng/ml), interferon (IFN)-g (200 UI/ml),
interleukin (IL)-1 (10 ng/ml), IL-6 (10 ng/ml)
and IL-15 (20 ng/ml). Results were normalized
against b-actin and relative TG2 mRNA levels
were referred to the non-stimulated control
(value = 1). Data represent means 6 standard
error of the mean (n = 3). The Mann–Whitney
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protein kinase (MAPK) and c-Jun N-terminal kinase (JNK)
[12]. In contrast, IFN-g may activate gene expression
through PI3-K or NF-kB pathways, among others [17]. To
investigate the signalling pathways involved in TG2 induc-
tion by IFN-g and TNF-a, specific inhibitors of well-
characterized pathways were used.
The quantitative analysis of TG2 mRNA in Caco-2 cells
stimulated with TNF-a, IFN-g or TNF-a + IFN-g in the
presence of selective inhibitors showed the contribution of
each signalling pathway on TG2 expression (Fig. 3).
Induction of TG2 by TNF-a was blocked completely in
the presence of SB203580 or sulphasalazine. Induction of
TG2 was inhibited partially in the presence of SP600125,
while wortmannin and Ly294002 had no effect. Wortman-
nin, Ly294002 and sulphasalazine were able to block the
induction of TG2 by IFN-g completely (Fig. 3).
When Caco-2 cells were treated with TNF-a and IFN-g,
the reduction in TG2 expression in the presence of the
inhibitors reflected the contribution of the individual sig-
nalling pathways to either TNF-a or IFN-g induction. For
example, SB203580 partially reduced the TG2 induction by
TNF-a + IFN-g, reflecting the inhibitory effect on the sig-
nalling pathways activated by TNF-a but not those acti-
vated by IFN-g. Sulphasalazine blocked the induction of
TG2 mRNA by TNF-a + IFN-g completely, highlighting the
central role of NF-kB in TG2 expression. These data show
that inhibition of NF-kB activity causes a potent suppres-
sion of TG2 expression. Although TNF-a and IFN-g drive
different signalling pathways, NF-kB is involved critically in
TG2 induction by both cytokines.
Similar results were obtained when TG2 expression was
evaluated in THP-1-induced cells in the presence of inhibi-
tors (Fig. 3), suggesting that the signalling pathways partici-
pating in TG2 induction by TNF-a and/or IFN-g are equally
active in both cell lines, even when these cells correspond to
developmentally separate lineages.
TG2 promoter is synergistically activated
by TNF-a + IFN-g
The earlier results showed that TNF-a and IFN-g activate
TG2 expression through different intracellular pathways.
Therefore, we sought to evaluate the synergistic effect of
TNF-a- and IFN-g-induced signals acting on the TG2
promoter. To this end, we cloned a fragment, 1·5 Kb long, of
the TG2 promoter from Caco-2 cells into a pGL3 luciferase
reporter plasmid. Caco-2 cells were transfected transiently
with the pTG2-luciferase plasmid and luciferase activity was
determined after 24 h of stimulation with TNF-a, IFN-g or
TNF-a + IFN-g (Fig. 4).
When compared to the respective single stimuli (2·44
RLU and 2·49 RLU for TNF-a and IFN-g, respectively),
we observed significantly enhanced TG2 activation
in Caco-2 incubated with TNF-a + IFN-g (5·54 RLU),
indicating that both cytokines activate the TG2 promoter
synergistically.
To evaluate the effect of specific inhibitors of signalling
pathways on the function of the TG2 promoter, pTG2-Luc
transiently transfected Caco-2 cells were incubated with
TNF-a + IFN-g alone or in the presence of Ly294002,
SP600125 or sulphasalazine (Fig. 4). The relative activity of
the TG2 promoter produced by TNF-a + IFN-g (5·54 RLU)
was similarly reduced by half that caused by the three inhibi-
tors tested (2·26 RLU, 2·36 and 2·28 for sulphasalazine,
Ly294002 and SP600125, respectively).
These data suggest that TG2 induction by TNF-a and
IFN-g occurs at transcriptional level through different intra-
cellular pathways which activate transcription factors that
bind to the TG2 promoter.
Next, we investigated whether the induction of TG2




































































Caco-2 HT29 A549 Calu-6 THP-1
Fig. 2. Tumour necrosis factor (TNF)-a and interferon (IFN)-g syn-
ergistically induce transglutaminase 2 (TG2) expression. Expression
of TG2 was determined by quantitative real time polymerase chain
reaction (RT–PCR) in Caco-2, HT29, A549, Calu-6 and THP-1 cells
(lower panel of the chart) stimulated for 24 h with TNF-a (10 ng/
ml), IFN-g (200 UI/ml) or a combination of both. Results were
normalized against b-actin and relative TG2 mRNA levels were
referred to the non-stimulated control (value = 1). Data represent
means 6 standard error of the mean (n = 3). The Mann–Whitney
U-test was performed: *P < 0·05; **P < 0·01.
IFNg and TNFa enhance TG2 expression
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protein level. To this purpose, TG2 was detected by Western
blot and flow cytometry.
Western blot analysis using the 4E1G9 anti-TG2 mono-
clonal antibody, which recognizes the epitope in position 637
to 648 located in the barrel 2 domain, confirmed that TG2
was expressed in untreated Caco-2 cells and was induced
strongly after 20 h of TNF-a + IFN-g treatment (Fig. 5).
To evaluate further whether inhibition of signalling path-
ways modulate TG2 expression at the protein level, Caco-2
cells were incubated with TNF-a + IFN-g in the presence
of inhibitors. Western blot analysis revealed that TG2 pro-
tein induction was inhibited when treatment with TNF-
a + IFN-g was performed in the presence of sulphasalazine
or wortmannin. The intensity of protein bands from TNF-
a + IFN-g-treated samples obtained in the presence of
inhibitors was similar to that obtained from untreated cells.
In order to evaluate further whether TG2 produced in
TNF-a + IFN-g-treated cells is correctly folded and located
at the cellular membrane, flow cytometric analysis was per-
formed on THP-1 cells stimulated with TNF-a + IFN-g for
20 h. A panel of four anti-TG2 monoclonal antibodies
(named 5G7G6, 2G3H8, 4E1G9 and 1H7H9), recognizing
different epitopes, was used to evaluate the surface expres-
sion of TG2. The four anti-TG2 antibodies detected TG2
on the cell surface [16]. Flow cytometric analysis, using
the 1H7H9 monoclonal antibody, showed that treatment
of THP-1 cells with TNF-a + IFN-g for 20 h increased
TG2 protein at the cellular membrane [mean fluorescence
intensity (MFI) = 30,78 in treated cells compared with
MFI = 16·41 for unstimulated cells (Fig. 6). Similar results
were obtained when flow cytometric analysis was performed
using the anti-TG2 monoclonal antibodies 4E1G9, 5G6G7
and 2G3H8 (not shown). To evaluate whether inhibition of
signalling pathways modulate the density of TG2 molecules
at the cell surface, flow cytometry was performed on THP-1
cells incubated for 20h with TNF-a + IFN-g in the presence
of inhibitors. Interestingly, the induction of TG2 protein
produced by the double stimulus with TNF-a + IFN-g was
blocked completely in the presence of sulphasalazine. When
the other inhibitors (Ly294002, SB203580, SP600125 and
wortmannin) were tested, the expression of surface TG2 was
only partially inhibited. These results are in accordance with
those obtained by qRT–PCR, Western blot and luciferase
activity analysis, and highlight the central role of NF-kB
activity on TG2 expression.
TNF-a + IFN-g up-regulate TG2 expression in human
small intestine mucosa
To investigate whether the synergistic induction of TG2 by
TNF-a + IFN-g in cell lines also occurred in intestinal tissue,
biopsy samples from the duodenum of untreated CD
patients and controls were incubated with the combination
of TNF-a + IFN-g for 24 h. Under basal conditions, intesti-
nal mucosa of untreated CD patients had a higher TG2
mRNA content (9·8-fold increase in comparison with the
housekeeping gene b-actin) than control samples (5·1-fold
increase) (Fig. 7a). Intestinal tissues from untreated CD
patients as well as controls showed up-regulation of TG2
mRNA (8·5- and 14·8-fold increase, respectively) when com-
pared to unstimulated samples. Surprisingly, intestinal
mucosa from untreated CD patients showed induction of
Fig. 3. Effect of inhibitors of signalling
pathways on transglutaminase 2 (TG2)
induction by tumour necrosis factor (TNF)-a
and interferon (IFN)-g. Caco-2 and THP-1
cells were incubated for 24 h with specific
inhibitors of signalling pathways: SP600125
(20 mM), SB203580 (10 mM), wortmannin
(10 mM), Ly294002 (2 mM), sulphasalazine
(10 mM) in the presence of TNF-a (10 ng/ml),
IFN-g (200 UI/ml) or the double stimulus
TNF-a + IFN-g. Level of TG2 transcripts
was determined by quantitative real time
polymerase chain reaction (RT–PCR). Results
were normalized with the housekeeping gene
b-actin and were referred to the non-stimulated
control (value = 1). Data represent
means 6 standard error of the mean (n = 4).
The Mann–Whitney U-test was performed:
*P < 0·05; **P < 0·01 (asterisks on individual
bars indicate comparison versus control). The
inserted chart indicates the signalling pathways
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TG2 mRNA by TNF-a + IFN-g, even when the local concen-
tration of proinflammatory cytokines is likely to be high due
to the chronic disease process observed in these patients.
Using specific inhibitors of activation pathways we next
explored whether the same signalling pathways observed in
Caco-2 or THP1 cells are active in intestinal tissues. To this
end, intestinal biopsies from the duodenum of CD patients
and controls were stimulated with TNF-a + IFN-g in
the presence of sulphasalazine or Ly294002 (Fig. 7b). The
inhibitors tested blocked the TG2 induction in both active
CD and control samples.
Therefore, induction of TG2 expression by TNF-a +
IFN-g was also observed in intestinal tissue, corroborating
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Fig. 4. Tumour necrosis factor (TNF)-a and interferon (IFN)-g
enhance transglutaminase 2 (TG2) promoter activity. Caco-2 cells
were transfected transiently with the pTG2–luciferase plasmid.
Luciferase activity (Dual LR System; Promega) was determined
after 24 h of stimulation with TNF-a (TNF-a 10 ng/ml), IFN-g
(200 UI/ml) or TNF-a + IFN-g alone or in the presence of
sulphasalazine (10 mM), Ly294002 (2 mM) or SP600125 (20 mM).
Relative luciferase units (RLU) are referred to the non-stimulated
control. Data represent means 6 standard error of the mean (n = 3).
The Mann–Whitney U-test was performed: *P < 0·05 (asterisks on










































Fig. 5. Tumour necrosis factor (TNF)-a and interferon (IFN)-g
induce transglutaminase 2 (TG2) synthesis. TG2 expression was
analysed by Western blot on protein extracts obtained from Caco-2
cells stimulated 20 h with TNF-a (10 ng/ml) and IFN-g (200 UI/ml)
(lane 2), medium (control, lane 3), (TNF-a + IFN-g) + sulphasalazine
(10 mM) (lane 4) and (TNF-a + IFN-g) + wortmannin (10 mM)
(lane 5). Anti-TG2 4E1G9 monoclonal antibody was used for TG2
detection. Detection of b-actin (Santa Cruz Biotechnology) was used
as normalizer. Recombinant TG2 (rTG2) (lane 1) produced in our


















Fig. 6. Tumour necrosis factor (TNF)-a and interferon (IFN)-g
induce surface expression of transglutaminase 2 (TG2). Surface TG2
expression was evaluated by flow cytometry on non-stimulated
THP-1 cells (grey line) or in cells stimulated for 20 h with TNF-a
(10 ng/ml) and IFN-g (200 UI/ml) either in the absence (black line)
or the presence of sulphasalazine (10 mM) (dashed line). Cells were
labelled with the 1H7H9 anti-TG2 monoclonal antibody or an isotype
control (grey histogram). Mean fluorescence intensity (MFI) values
are indicated for each histogram.
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Discussion
TG2 is a cross-linking enzyme involved in several cellular
processes under normal physiological conditions such as cell
adhesion, migration, cell cycle, apoptosis and differentiation.
TG2 also plays important roles in inflammatory diseases
and, as it can either promote or inhibit cell death, also has
a role in cancer [5–7].
TG2 is up-regulated strongly in villus atrophy, the hall-
mark histological lesion in CD, and plays a critical role in
CD pathogenic mechanisms due to the generation of
neoepitopes by selective deamidation of glutamines in
gluten peptides. This reaction produces peptides with
higher-affinity binding to the known HLA class II suscepti-
bility molecules and promotes a stronger activation and
expansion of gliadin-specific IFN-g-producing CD4+ T cells
[8–10]. In addition, the continuous activation of TG2 may
lead to chronic inflammation by cross-linking and the loss of
function of peroxisome proliferator-activated receptor-g
(PPARg), a central mediator of intestinal homeostasis
[18]. Other proinflammatory effects have been described for
TG2, including the production of IL-6, a proinflammatory
cytokine and also a potent signal for driving T helper type
17 (Th17) differentiation [19]. This suggests that TG2
may trigger other inflammatory mediators and favour
Th17 expansion, which together may constitute an
additional potent inducer for chronic inflammation and
autoimmunity. Therefore, modulation of TG2 expression
may be a specific tool for the therapeutic management of
different inflammatory disorders.
In the current study, we demonstrated that the proinflam-
matory cytokines TNF-a, IFN-g, IL-1, IL-15 and IL-6
induced TG2 expression to different extents, with IFN-g
being the most potent inducers of TG2 expression, followed
by TNF-a. These two cytokines up-regulated TG2 mRNA
expression synergistically, with maximal induction observed
at 16 h post-treatment (Figs 1, 2 and Supporting Informa-
tion, Fig. S3). Notably, the results were similar for the five
human cell lines tested (two from intestinal epithelia, two
from lung epithelia and one monocytic-like), suggesting the
presence of similar mechanisms for the control of TG2
expression in these cells. Consequently, this observation
could be extended to pathophysiological processes in which
TG2 has been implicated, such as neurodegenerative disor-
ders, where the cytokines mentioned above produced by
microglia cells (monocytic-like) have been suggested to play
a role [11].
Using a set of specific inhibitors [20–22] we were able to
identify the main signalling pathways activated by TNF-a
and IFN-g that regulate the activity of the TG2 promoter.
TNF-a activated the expression of TG2 through p38 MAPk,
NF-kB and JNK. The p38 MAPK, probably acting through
the AP-1 binding sites on TG2 promoter, was blocked by
SB203580 (pyridinyl imidazole) [23,24]. Inhibition of JNK
activity by SP600125 (anthrapyrazolone) caused only a
partial reduction of the TG2 expression induced by TNF-a.
The NF-kB pathway seems to have a central role in TG2
expression after activation by both TNF-a or IFN-g, as the
use of two inhibitors, sulphasalazine (sulpha drug, derivative
of mesalazine, and a potent and specific inhibitor of NF-kB)
and BAY11-7082 (inhibits NF-kB by blocking cytokine-
induced IkB-a phosphorylation), completely abrogated the
TG2 induction (Fig. 3).
Different studies have shown that signalling pathways
induced by IFN-g involve activation of PI3K or NF-kB
[17,24]. Upon activation, PI3-K mediates the recruit-
ment and phosphorylation of Akt at Serine 473, a
known target of PI3-K [17]. In the present study, the
Fig. 7. Transglutaminase 2 (TG2) expression
in human small intestinal mucosa. Duodenal
samples from untreated coeliac disease (CD)
patients (n = 5) and control individuals (n = 7)
were incubated for 24 h with tumour necrosis
factor (TNF)-a (10 ng/ml) and interferon
(IFN)-g (200 UI/ml) or medium (NS) (a)
or with TNF-a + IFN-g in the presence of
sulphasalazine (10 mM) or Ly294002 (2 mM)
(b). In (a) the levels of TG2 transcript were
determined by quantitative real time
polymerase chain reaction (RT–PCR) as
fold increase (DCt) in comparison with the
housekeeping gene (b-actin). In (b), the fold
increase (2^DCt) of the TG2 transcript was
normalized with the housekeeping gene
(b-actin) and referred to the unstimulated
tissue from each patient. Mann–Whitney


















































































































M. Bayardo et al.
102 © 2011 The Authors
Clinical and Experimental Immunology © 2011 British Society for Immunology, Clinical and Experimental Immunology, 168: 95–104
pharmacological inhibitors of PI3-K pathway, LY294002
[17] and wortmannin [25], inhibited significantly the effects
of IFN-g.
Interestingly, using T84 cells, a human intestinal epithelial
cell line, Professor C. Khosla and colleagues (personal com-
munication) demonstrated that IFN-g increases TG2 activity
through a PI3K-dependent mechanism. The use of the PI3K
inhibitor, LY294002, blocked the extracellular activation of
TG2 and emerged as an attractive pharmacological agent for
treatment of CD.
Bioinformatic analyses (MatInspector Genomatix) of the
TG2 promoter region showed the presence of binding sites
for several transcription factors involved directly in proin-
flammatory pathways, such as SP1, ZBP, SMADs, GATAs,
AP-1, NF-kB and signal transducers and activation of tran-
scription (STATs), among others. Undoubtedly, the NF-kB
pathway has been the one most intensively studied. TG2 is
also able to control NF-kB activation by depleting the IkBa
inhibitor via polymer formation, explaining a direct cross-
activation between NF-kB and TG2 [11].
Using a luciferase reporter assay in Caco-2 cells (Fig. 4),
we demonstrated the activity of some of the putative binding
sites for transcriptional factors in the TG2 promoter, as
predicted by bioinformatics.
Expression of TG2 at protein level was evaluated by
Western blot analysis, revealing the synergistic induction by
TNF-a + IFN-g (Fig. 5). More importantly, analysis by flow
cytometry using a panel of conformational specific anti-TG2
monoclonal antibodies allowed us to evaluate the correct
folding and location of TG2 at the cellular surface and the
effect of the different inhibitors on TG2 expression (Fig. 6).
We next analysed whether the signalling pathways identi-
fied by in-vitro assays on cell lines also operate in intestinal
tissue. Basal TG2 expression was detected in healthy tissue,
but levels were significantly higher in samples from
untreated CD patients (Fig. 7). Incubation with TNF-
a + IFN-g induced TG2 expression in biopsy samples from
both CD patients and control individuals. Therefore, TG2 is
expressed physiologically in healthy mucosal tissue and is
increased in intestinal mucosa of untreated CD patients, as a
consequence of the proinflammatory environment in intes-
tinal mucosa in active CD, due mainly to abundant IFN-g, a
key player in the pathogenic mechanism of CD.
Because IkBa is a key negative modulator of the NF-kB
pathway, inactivation of IkBa by cross-linking induced
strongly by TG2 activates NF-kB. Consequently, TG2 and
NF-kB can enhance each other’s actions amplifying the
inflammatory cycle [11]. Interestingly, constitutive NF-kB
activation often accompanies increased TG2 expression in
inflammatory disease such as inflammatory bowel disease,
rheumatoid arthritis and coeliac disease [6,7,26,27]. Similar
to NF-kB, other transcription factors that activate TG2 also
induce the production of proinflammatory cytokines char-
acteristically present in the intestinal mucosa of untreated
CD patients. Therefore, NF-kB, as a key element together
with others transcription factors, may exacerbate a complex
vicious circle of inflammation through interactions with
TG2.
Induction of these inflammatory pathways drives activa-
tion and recruitment of effector cells, such as neutrophils,
macrophages, dendritic cells and T cells, which cause and
amplify the pathogenic mechanisms of different chronic
disorders [7,28,29].
Based on our results obtained by qRT–PCR, flow cytom-
etry and Western blotting, we propose a model for the sig-
nalling pathways activated by TNF-a and IFN-g involved
in the regulation of TG2 expression. As a consequence of
dysregulation of TG2 expression and activity, a distinct
pathogenic process may be initiated (Fig. 8).
Therapeutic approaches aimed to modulate the activity of
TG2 are being taken into consideration as a way to reduce, or
even cancel, the disease processes in which the enzyme is
involved [15,30]. This study on TG2 gene regulation pro-
vides useful information for the development of new thera-
peutic strategies to down-modulate chronic inflammatory
disorders.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Fig. S1. Dose–response curve of transglutaminase 2 (TG2)
induction by tumour necrosis factor (TNF)-a and interferon
(IFN)-g. Human acute monocytic leukaemia cell line
(THP-1) cells were incubated for 24 h with different concen-
trations of TNF-a and/or IFN-g as indicated. Grey bars cor-
respond to the cytokine concentration selected for further
studies; TNF-a (10 ng/ml) and IFN-g (200 UI/ml).
Fig. S2. Cell viability after cytokine treatments. Cell viability
was determined by Trypan blue exclusion in human acute
monocytic leukaemia cell line (THP-1) cells treated for 24 h
with different concentrations of tumour necrosis factor
(TNF)-a and/or interferon (IFN)-g as indicated. Grey bars
correspond to the cytokine concentration selected for
further studies; TNF-a (10 ng/ml) and IFN-g (200 UI/ml).
Fig. S3. Kinetic of transglutaminase 2 (TG2) induction
by tumour necrosis factor (TNF)a + interferon (IFN)-g.
Caco-2 and human acute monocytic leukaemia cell line
(THP-1) cells were incubated for different times with TNF-a
(10 ng/ml) and IFN-g (200 UI/ml). Levels of TG2 transcript
were determined by quantitative real time–polymerase
chain reaction (RT–PCR). Results were normalized against
b-actin and relative TG2 mRNA levels were referred to
the non-stimulated control (value = 1). Data represent
means 6 standard error of the mean (n = 3). The Mann–
Whitney U-test was performed: *P < 0·05; **P < 0·01.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing mate-
rial) should be directed to the corresponding author for the
article.
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